Royalty Pharma plc
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $674.1M | $630.6M | $622.0M | $609.3M | $578.7M | $568.2M | $593.6M | $564.7M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $97.9M | $39.8M | $50.5M | $50.5M | $300.5M | $50.5M | $500.0K | $500.0K |
| SG&A Expense | $161.9M | $159.5M | $164.3M | $118.7M | $179.8M | $110.7M | $67.6M | $56.7M |
| Operating Income | $133.1M | $563.0M | $388.4M | $427.2M | $209.8M | $534.2M | $361.5M | $735.1M |
| Operating Margin | 19.7% | 89.3% | 62.4% | 70.1% | 36.3% | 94.0% | 60.9% | 130.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $81.5M | $468.3M | $352.9M | $444.2M | $92.6M | $434.4M | $334.4M | $806.4M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $17.9M | $294.7M | $211.2M | $288.2M | $32.2M | $239.3M | $208.2M | $544.0M |
| Net Margin | 2.7% | 46.7% | 34.0% | 47.3% | 5.6% | 42.1% | 35.1% | 96.3% |
| EPS (Basic) | $0.04 | $0.67 | $0.49 | $0.67 | $0.08 | $0.55 | $0.46 | $1.22 |
| EPS (Diluted) | $0.04 | $0.67 | $0.49 | $0.67 | $0.07 | $0.55 | $0.46 | $1.21 |
| Shares Outstanding (Basic) | 445.1M | 436.8M | 429.8M | 431.9M | 423.5M | 435.5M | 448.2M | 447.6M |
| Shares Outstanding (Diluted) | 556.9M | 556.8M | 564.5M | 559.6M | 562.3M | 578.1M | 594.1M | 592.7M |
| Dividends Per Share | $0.24 | $0.24 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 |